Cargando…
Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study
BACKGROUND: The GABA(A)-α5 receptor antagonist S44819 is a promising candidate to enhance functional recovery after acute ischemic stroke (IS). S44819 is currently evaluated in this indication; RESTORE brain study started in Dec 2016 and was completed in March 2019. METHODS/DESIGN: The study is a 3-...
Autores principales: | Chabriat, Hugues, Bassetti, Claudio L., Marx, Ute, Picarel-Blanchot, Françoise, Sors, Aurore, Gruget, Celine, Saba, Barbara, Wattez, Marine, Audoli, Marie-Laure, Hermann, Dirk M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998064/ https://www.ncbi.nlm.nih.gov/pubmed/32014032 http://dx.doi.org/10.1186/s13063-020-4072-2 |
Ejemplares similares
-
Preclinical concepts and results with the GABA(A) antagonist S44819 in a mouse model of middle cerebral artery occlusion
por: Hermann, Dirk M., et al.
Publicado: (2019) -
Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France
por: Gorwood, Philip, et al.
Publicado: (2020) -
The safety of agomelatine in standard medical practice in depressed patients: A 26‐week international multicentre cohort study
por: Gorwood, Philip, et al.
Publicado: (2020) -
Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies
por: Stein, Dan J., et al.
Publicado: (2021) -
Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review
por: Bougeard, Clémence, et al.
Publicado: (2021)